Key Highlights
- Tempus partners with JW Pharmaceutical to advance AI-driven cancer research.
- Utilizes real-world data (RWD) and biological modeling in early-stage oncology research.
- Patient-derived organoid models aid in biomarker discovery and asset prioritization.
- Collaboration aligns with global trends in data-driven drug development.
- Expected to enhance Korea’s domestic drug development landscape.
Source: Business Wire
Notable Quotes
- “We are excited to work with a forward-looking collaborator like JW Pharmaceutical, a pioneer in Korea that is embracing the power of RWD and AI to advance the next generation of cancer therapeutics.” — Ryan Fukushima, COO at Tempus
- “This collaboration marks a turning point in data-driven drug development using RWD in Korea, aligning with global trends and expected to positively impact the domestic drug development landscape.” — Chan-Hee Park, CTO at JW Pharmaceutical
SoHC's Take
This strategic partnership between Tempus and JW Pharmaceutical showcases a significant advancement in the integration of real-world data and AI within the field of oncology. By combining Tempus’ extensive multimodal dataset and organoid models with JW’s focus on early therapeutic research, this collaboration promises accelerated drug discovery and a pioneering approach to biomarker identification and asset screening. As Korea’s pharmaceutical landscape continues to evolve, this move aligns with global standards and positions JW Pharmaceutical as a leader in the data-driven, AI-enhanced era of oncology therapeutics.
